"Novo Nordisk (NVO)"
This is a series of Phase 3 trials studying retatrutide across multiple conditions: TRIUMPH-1 : Obesity (basket trial with nested OSA and OA protocols) TRIUMPH-2 : Obesity in type 2 diabetes population (with nested OSA) TRIUMPH-3 : Weight management in cardiovascular disease population TRIUMPH-4 : Obesity with knee osteoarthritis (completed results December 2025) Additional trials covering MASLD (metabolic dysfunction-associated steatotic liver disease), cardiovascular/renal outcomes, chronic low back pain, and weight maintenance TRANSCEND program: Dedicated type 2 diabetes trials (separate from TRIUMPH) TRIUMPH-4 was the first Phase 3 trial to report results, announced in December 2025
Some people find that eating lighter meals for 24 to 48 hours after their weekly injection, when the medication effect is peaking and gastric emptying is most delayed, significantly reduces sulfur burp severity
What your doctor should know about your heartburn Coming prepared to your medical appointment makes a significant difference in the quality of care you receive
GLP-1s: Promise and problems "GLP-1 medications are great, and there are similar promising drugs in the pipeline," says Dr
iScience 2022;25:104085.ArticlePubMedPMC 67
